Prevention of diseases caused by Staphylococcus aureus using the peptide RIP

被引:72
作者
Balaban, N [1 ]
Collins, LV
Cullor, JS
Hume, EB
Medina-Acosta, E
da Motta, OV
O'Callaghan, R
Rossitto, PV
Shirtliff, ME
da Silveira, LS
Tarkowski, A
Torres, JV
机构
[1] Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA
[2] Univ Gothenburg, Dept Rheumatol, S-41346 Gothenburg, Sweden
[3] Univ Calif, Dairy Food Safety Lab, Vet Med Teaching & Res Ctr, Tulare, CA 93274 USA
[4] Louisiana State Univ, Med Ctr, Sch Med, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA
[5] Univ Estadual Norte Fluminense, Biotechnol Lab, Ctr Biosci & Biotechnol, Rio De Janeiro, Brazil
[6] Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA
[7] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA
关键词
D O I
10.1016/S0196-9781(00)00272-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S, aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1301 / 1311
页数:11
相关论文
共 51 条
[1]   Frequency of α- and β-haemolysin in Staphylococcus aureus of bovine and human origin -: A comparison between pheno- and genotype and variation in phenotypic expression [J].
Aarestrup, FM ;
Larsen, HD ;
Eriksen, NHR ;
Elsberg, CS ;
Jensen, NE .
APMIS, 1999, 107 (04) :425-430
[2]   Development of penicillin resistance among Staphylococcus aureus isolated from bovine mastitis in Denmark and other countries [J].
Aarestrup, FM ;
Jensen, NE .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1998, 4 (03) :247-256
[3]   TOXIC-SHOCK-SYNDROME TOXIN-1 CONTRIBUTES TO THE ARTHRITOGENICITY OF STAPHYLOCOCCUS-AUREUS [J].
ABDELNOUR, A ;
BREMELL, T ;
TARKOWSKI, A .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (01) :94-99
[4]   THE ACCESSORY GENE REGULATOR (AGR) CONTROLS STAPHYLOCOCCUS-AUREUS VIRULENCE IN A MURINE ARTHRITIS MODEL [J].
ABDELNOUR, A ;
ARVIDSON, S ;
BREMELL, T ;
RYDEN, C ;
TARKOWSKI, A .
INFECTION AND IMMUNITY, 1993, 61 (09) :3879-3885
[5]  
[Anonymous], 2000, SCIENCE, DOI DOI 10.1126/SCIENCE.287.5452.391A
[6]   ULCERATIVE KERATITIS - SURVEY OF 30 YEARS LABORATORY EXPERIENCE [J].
ASBELL, P ;
STENSON, S .
ARCHIVES OF OPHTHALMOLOGY, 1982, 100 (01) :77-80
[7]   AUTOCRINE REGULATION OF TOXIN SYNTHESIS BY STAPHYLOCOCCUS-AUREUS [J].
BALABAN, N ;
NOVICK, RP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1619-1623
[8]   Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus [J].
Balaban, N ;
Goldkorn, T ;
Nhan, RT ;
Dang, LB ;
Scott, S ;
Ridgley, RM ;
Rasooly, A ;
Wright, SC ;
Larrick, JW ;
Rasooly, R ;
Carlson, JR .
SCIENCE, 1998, 280 (5362) :438-440
[9]  
BALABAN N, 2000, SCIENCE, V287, pA391
[10]   The molecular architecture of the sar locus in Staphylococcus aureus [J].
Bayer, MG ;
Heinrichs, JH ;
Cheung, AL .
JOURNAL OF BACTERIOLOGY, 1996, 178 (15) :4563-4570